US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5614184A
(en)
*
|
1992-07-28 |
1997-03-25 |
New England Deaconess Hospital |
Recombinant human erythropoietin mutants and therapeutic methods employing them
|
US6153407A
(en)
*
|
1992-07-28 |
2000-11-28 |
Beth Israel Deaconess Medical Center |
Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
|
AU6709794A
(en)
*
|
1993-04-21 |
1994-11-08 |
Brigham And Women's Hospital |
Erythropoietin muteins with enhanced activity
|
ZA946122B
(en)
*
|
1993-08-17 |
1995-03-20 |
Amgen Inc |
Erythropoietin analogs
|
US5773569A
(en)
*
|
1993-11-19 |
1998-06-30 |
Affymax Technologies N.V. |
Compounds and peptides that bind to the erythropoietin receptor
|
US5830851A
(en)
*
|
1993-11-19 |
1998-11-03 |
Affymax Technologies N.V. |
Methods of administering peptides that bind to the erythropoietin receptor
|
US5696250A
(en)
*
|
1995-02-15 |
1997-12-09 |
Amgen Inc. |
DNA encoding megakaryocyte growth and development factor analogs
|
US5989538A
(en)
*
|
1995-02-15 |
1999-11-23 |
Amgen Inc. |
Mpl ligand analogs
|
EP1731174A3
(en)
|
1996-08-02 |
2007-01-17 |
Ortho-McNeil Pharmaceutical, Inc. |
Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
IL124015A0
(en)
|
1998-04-08 |
1999-01-26 |
Yeda Res & Dev |
Pharmaceutical compositions comprising a protein
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
CA2326384A1
(en)
|
1998-04-22 |
1999-10-28 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
EP1088084B1
(en)
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion protein
|
US6210924B1
(en)
|
1998-08-11 |
2001-04-03 |
Amgen Inc. |
Overexpressing cyclin D 1 in a eukaryotic cell line
|
US7304150B1
(en)
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
SI1813624T1
(sl)
*
|
1998-10-23 |
2010-12-31 |
Amgen Inc |
Postopki in sestavki za prepeäśevanje in zdravljenje anemije
|
BR9905868A
(pt)
*
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
|
EP1135493A2
(en)
*
|
1998-11-30 |
2001-09-26 |
Eli Lilly And Company |
Erythropoietic compounds
|
US6703480B1
(en)
|
1999-11-24 |
2004-03-09 |
Palani Balu |
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
PT1274728E
(pt)
|
2000-04-21 |
2008-06-20 |
Amgen Inc |
Métodos e composições para a prevenção e tratamento de anemia
|
AU2001276737A1
(en)
|
2000-08-04 |
2002-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Protein injection preparations
|
ES2644275T3
(es)
|
2000-08-11 |
2017-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Preparaciones estabilizadas que contienen anticuerpos
|
US7855229B2
(en)
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7645898B2
(en)
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
PA8536201A1
(es)
*
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
PL206701B1
(pl)
|
2001-03-07 |
2010-09-30 |
Merck Patent Gmbh |
Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
|
WO2002072615A1
(fr)
|
2001-03-09 |
2002-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methode de purification de proteines
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
JP4236934B2
(ja)
|
2001-04-17 |
2009-03-11 |
中外製薬株式会社 |
界面活性剤の定量方法
|
DE60239454D1
(de)
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
BR0213402A
(pt)
|
2001-10-29 |
2004-10-13 |
Crucell Holland Bv |
Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
NZ537306A
(en)
*
|
2002-07-01 |
2008-11-28 |
Kenneth S Warren Inst Inc |
Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
|
JP4489591B2
(ja)
|
2002-08-27 |
2010-06-23 |
中外製薬株式会社 |
タンパク質溶液製剤の安定化方法
|
SI2261230T1
(sl)
|
2002-09-11 |
2017-08-31 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek čiščenja proteinov
|
DE20321793U1
(de)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkylstärke-Derivate
|
CA2496317C
(en)
|
2002-09-11 |
2014-02-18 |
Fresenius Kabi Deutschland Gmbh |
Method of producing hydroxyalkyl starch derivatives
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
AU2003273413A1
(en)
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
MXPA05006384A
(es)
|
2002-12-17 |
2005-08-29 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
US7645733B2
(en)
|
2003-09-29 |
2010-01-12 |
The Kenneth S. Warren Institute, Inc. |
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
|
NZ548612A
(en)
|
2004-02-09 |
2009-11-27 |
Human Genome Sciences Inc |
Albumin fusion proteins comprising tandem GLP-1
|
SG151261A1
(en)
|
2004-03-11 |
2009-04-30 |
Fresenius Kabi De Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
WO2006089228A2
(en)
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US9988427B2
(en)
|
2005-05-13 |
2018-06-05 |
Charite Universitaetsmedizen-Berlin |
Erythropoietin variants
|
ES2453981T3
(es)
|
2005-08-31 |
2014-04-09 |
University Of Tennessee Research Foundation |
Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM)
|
CA2630811C
(en)
|
2005-12-08 |
2016-05-31 |
Amgen Inc. |
Improved production of glycoproteins using manganese
|
ES2434494T3
(es)
|
2005-12-08 |
2013-12-16 |
Amgen, Inc. |
Células huésped mejoradas y métodos de cultivo
|
CN101365719A
(zh)
*
|
2006-01-18 |
2009-02-11 |
中外制药株式会社 |
唾液酸的去除方法及去唾液酸促红细胞生成素的制备方法
|
WO2007108505A1
(ja)
|
2006-03-22 |
2007-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
エリスロポエチン溶液製剤
|
WO2007142288A1
(ja)
|
2006-06-07 |
2007-12-13 |
The University Of Tokushima |
エリスロポエチンを用いた虚血性疾患の治療
|
KR101460999B1
(ko)
|
2006-07-12 |
2014-11-17 |
유니버시티 오브 테네시 리서치 파운데이션 |
치환된 아실아닐리드 및 그의 사용 방법
|
US20090173876A1
(en)
|
2006-07-21 |
2009-07-09 |
Amgen Inc. |
Method of detecting and/or measuring hepcidin in a sample
|
EP2630972B1
(en)
*
|
2006-07-25 |
2017-08-30 |
Lipoxen Technologies Limited |
N-terminal polysialylation
|
CA2661054A1
(en)
|
2006-08-22 |
2008-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Prophylactic and/or therapeutic agents for peripheral neuropathy
|
BRPI0714526A2
(pt)
|
2006-08-24 |
2013-04-30 |
Univ Tennessee Res Foundation |
acilanilidas substituÍdas e seus mÉtodos de uso
|
WO2008058942A2
(en)
|
2006-11-13 |
2008-05-22 |
Charite - Universitätsmedezin Berlin |
Method of cell culture and method of treatment comprising a vepo protein variant
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
CA2701032C
(en)
|
2007-09-27 |
2021-01-26 |
Amgen Inc. |
Pharmaceutical formulations
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
AU2009206306B2
(en)
|
2008-01-25 |
2013-06-06 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
WO2009139822A1
(en)
|
2008-05-01 |
2009-11-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
DE102008002209A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur Aufreinigung von Erythropoietin
|
WO2009155481A1
(en)
|
2008-06-20 |
2009-12-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
EP2161031A1
(en)
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
|
JP5632376B2
(ja)
*
|
2008-09-23 |
2014-11-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
エリスロポエチンの精製
|
AU2009313902B9
(en)
|
2008-11-13 |
2014-03-27 |
The General Hospital Corporation |
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
|
DE102008054716A1
(de)
|
2008-12-16 |
2010-06-17 |
Evonik Degussa Gmbh |
Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
|
WO2011011674A2
(en)
|
2009-07-24 |
2011-01-27 |
Dr. Reddy's Laboratories Ltd. |
Production of erythropoiesis stimulating protein using metal ions
|
CN102712688B
(zh)
|
2009-09-23 |
2015-06-24 |
通益制药有限公司 |
重组人红细胞生成素(epo)的纯化方法、由此纯化的epo以及包含纯化的epo的药物组合物
|
US9662271B2
(en)
|
2009-10-23 |
2017-05-30 |
Amgen Inc. |
Vial adapter and system
|
EP2575935B2
(en)
|
2010-06-07 |
2023-08-23 |
Amgen Inc. |
Drug delivery device
|
CA2831100C
(en)
|
2011-03-31 |
2020-02-18 |
Mark Dominis Holt |
Vial adapter and system
|
CA3021845C
(en)
|
2011-04-20 |
2022-03-29 |
Amgen Inc. |
Autoinjector apparatus
|
IL301153B2
(en)
|
2011-10-14 |
2024-05-01 |
Amgen Inc |
Syringe and assembly method
|
EP2836504B1
(en)
*
|
2012-04-10 |
2018-11-14 |
Dr. Reddy's Laboratories Limited |
Single step fractionation method
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
KR102122941B1
(ko)
|
2012-07-13 |
2020-06-15 |
지티엑스, 인코포레이티드 |
선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
|
EP4234694A3
(en)
|
2012-11-21 |
2023-09-06 |
Amgen Inc. |
Drug delivery device
|
EP3524691A1
(en)
|
2012-12-07 |
2019-08-14 |
SuppreMol GmbH |
Stratification and treatment of patients of idiopathic thrombocytopenic purpura
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
DK2968503T3
(en)
|
2013-03-15 |
2018-12-03 |
Intrinsic Lifesciences Llc |
ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
|
TWI580452B
(zh)
|
2013-03-15 |
2017-05-01 |
安美基公司 |
用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法
|
CN105377327B
(zh)
|
2013-03-22 |
2021-06-22 |
安姆根有限公司 |
注射器及装配方法
|
SG11201602876WA
(en)
|
2013-10-24 |
2016-05-30 |
Amgen Inc |
Injector and method of assembly
|
EP3060281B1
(en)
|
2013-10-24 |
2019-01-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
WO2015130963A2
(en)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
US10722655B2
(en)
|
2014-05-07 |
2020-07-28 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
SG11201609050UA
(en)
|
2014-05-30 |
2016-12-29 |
Pfizer |
Carbonitrile derivatives as selective androgen receptor modulators
|
CN106470716B
(zh)
|
2014-06-03 |
2020-07-17 |
安姆根有限公司 |
可控制药物递送系统和使用方法
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
CA2957960C
(en)
|
2014-10-14 |
2023-08-22 |
Amgen, Inc. |
Drug injection device with visual and audible indicators
|
EP3233159B1
(en)
|
2014-12-19 |
2020-03-04 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
ES2898469T3
(es)
|
2014-12-19 |
2022-03-07 |
Amgen Inc |
Dispositivo de administración de medicamentos con sensor de proximidad
|
JP6484345B2
(ja)
|
2015-02-17 |
2019-03-20 |
アムジエン・インコーポレーテツド |
固定及び/または戻りが真空によって支援された薬物送達装置
|
US11806509B2
(en)
|
2015-02-27 |
2023-11-07 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
US11351308B2
(en)
|
2015-12-09 |
2022-06-07 |
Amgen Inc. |
Auto-injector with signaling cap
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
EP4035711A1
(en)
|
2016-03-15 |
2022-08-03 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
US10988284B2
(en)
|
2016-05-13 |
2021-04-27 |
Amgen Inc. |
Vial sleeve assembly
|
EP3458988B1
(en)
|
2016-05-16 |
2023-10-18 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
EP3465124A1
(en)
|
2016-06-03 |
2019-04-10 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
EP3478342A1
(en)
|
2016-07-01 |
2019-05-08 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
US11369736B2
(en)
|
2017-02-17 |
2022-06-28 |
Amgen Inc. |
Cannula insertion and retraction mechanisms
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
WO2018165143A1
(en)
|
2017-03-06 |
2018-09-13 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
EP3592402A1
(en)
|
2017-03-07 |
2020-01-15 |
Amgen Inc. |
Needle insertion by overpressure
|
MX2019010671A
(es)
|
2017-03-09 |
2019-10-21 |
Amgen Inc |
Mecanismo de insercion para dispositivo de administracion de farmacos.
|
CN110446499A
(zh)
|
2017-03-20 |
2019-11-12 |
豪夫迈·罗氏有限公司 |
一种体外糖基工程化红细胞生成刺激蛋白的方法
|
BR112019020053B1
(pt)
|
2017-03-28 |
2023-10-10 |
Amgen Inc |
Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
|
AU2018280054B2
(en)
|
2017-06-08 |
2023-07-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
US11904143B2
(en)
|
2017-06-08 |
2024-02-20 |
Amgen Inc. |
Torque driven drug delivery device
|
CA3063920A1
(en)
|
2017-06-22 |
2018-12-27 |
Amgen Inc. |
Device activation impact/shock reduction
|
US11395880B2
(en)
|
2017-06-23 |
2022-07-26 |
Amgen Inc. |
Electronic drug delivery device
|
MA49562A
(fr)
|
2017-07-14 |
2020-05-20 |
Amgen Inc |
Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
|
EP3655063A1
(en)
|
2017-07-21 |
2020-05-27 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
EP4085942A1
(en)
|
2017-07-25 |
2022-11-09 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
US11484648B2
(en)
|
2017-07-25 |
2022-11-01 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
MA49838A
(fr)
|
2017-08-09 |
2020-06-17 |
Amgen Inc |
Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
|
EP3668567A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
MA50611A
(fr)
|
2017-10-04 |
2020-08-12 |
Amgen Inc |
Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
|
WO2019070552A1
(en)
|
2017-10-06 |
2019-04-11 |
Amgen Inc. |
DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
|
US11464903B2
(en)
|
2017-10-09 |
2022-10-11 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
EP3703778A1
(en)
|
2017-11-03 |
2020-09-09 |
Amgen Inc. |
System and approaches for sterilizing a drug delivery device
|
CA3079197A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
US20200338271A1
(en)
|
2017-11-06 |
2020-10-29 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
CN116832271A
(zh)
|
2017-11-10 |
2023-10-03 |
安进公司 |
用于药物递送装置的柱塞
|
CN111263651B
(zh)
|
2017-11-16 |
2022-06-17 |
安进公司 |
具有停顿和终点检测的自动注射器
|
MX2020004996A
(es)
|
2017-11-16 |
2020-08-27 |
Amgen Inc |
Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
WO2020023451A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
MA53379A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Dispositifs d'administration pour l'administration de médicaments
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
US20210228797A1
(en)
|
2018-07-31 |
2021-07-29 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
AU2019347710A1
(en)
|
2018-09-24 |
2021-02-04 |
Amgen Inc. |
Interventional dosing systems and methods
|
CA3110371A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
MA53815A
(fr)
|
2018-10-02 |
2022-01-05 |
Amgen Inc |
Systèmes d'injection pour administration de médicament avec transmission de force interne
|
US20210338936A1
(en)
|
2018-10-05 |
2021-11-04 |
Amgen Inc. |
Drug delivery device having dose indicator
|
TW202031306A
(zh)
|
2018-10-15 |
2020-09-01 |
美商安進公司 |
用於藥物遞送裝置之平台組裝方法
|
US20200114082A1
(en)
|
2018-10-15 |
2020-04-16 |
Amgen Inc. |
Drug delivery device having damping mechanism
|
WO2020091981A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
WO2020091956A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
AU2020263289A1
(en)
|
2019-04-24 |
2021-09-16 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
US20220273887A1
(en)
|
2019-08-23 |
2022-09-01 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
EP4341161A1
(en)
|
2021-05-21 |
2024-03-27 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|